Clinical trials: Non-Small Cell Lung
EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
The purpose of this study is to compare 3years of disease-free survival (DFS) of Icotinib and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.
- Trial name
- ICWIP (NCT02125240)
- Testing
- Icotinib
- Where
- 11 sites in China
- Volunteers
- 124 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer Metastatic
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC
This is a randomized, multicenter, multinational, double-blind, and parallel-group study to evaluate the PK, efficacy, safety and immunogenicity of MB12 (proposed pembrolizumab biosimilar) versus Keytruda® in subjects with newly…
- Trial name
- NCT05668650
- Testing
- Pembrolizumab, Pembrolizumab biosimilar
- Where
- Argentina
- Volunteers
- 174 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Non-Small Cell Lung Cancer, Lung Cancer
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation…
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
- Trial name
- NCT06685718
- Testing
- BG-60366
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 33 people
- Sponsor
- BeOne Medicines
Cancer
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00630110
- Testing
- docetaxel, NPI-2358 + docetaxel
- Where
- 36 sites in United States, Argentina and 4 more
- Volunteers
- 172 people
- Sponsor
- Nereus Pharmaceuticals, Inc.
Non-small Cell Lung Cancer (NSCLC)
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
The purpose was to evaluate the efficacy and safety of the combination of capmatinib with pembrolizumab compared to pembrolizumab alone as first-line treatment for subjects with locally advanced or metastatic NSCLC who have PD-L1…
- Trial name
- NCT04139317
- Testing
- Capmatinib, Pembrolizumab
- Where
- 36 sites in Australia, Belgium and 14 more
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Nonsmall Cell Lung Cancer
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.
- Trial name
- NCT04396340
- Testing
- XMT-1592
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mersana Therapeutics
Carcinoma, Non-Small Cell Lung
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
- Trial name
- NCT00300885
- Testing
- Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 926 people
- Sponsor
- Bayer
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer…
- Conditions
- Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- Trial name
- NCT07222566
- Testing
- PF-08634404, Pembrolizumab, Chemotherapy Regimen 1
- Where
- 484 sites in United States, Argentina and 18 more
- Volunteers
- 1,410 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer NSCLC
Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in…
- Trial name
- CODAK (NCT04667312)
- Testing
- Durvalumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 115 people
- Sponsor
- AstraZeneca
Solid Tumor, Non-small Cell Lung Cancer
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05369312
- Testing
- BPI-442096
- Where
- 5 sites in China
- Volunteers
- 230 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer
- Trial name
- NCT06883630
- Testing
- RC148 plus Carboplatin and Paclitaxel/pemetrexed, RC148
- Where
- 24 sites in China
- Volunteers
- 121 people
- Sponsor
- RemeGen Co., Ltd.
Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
This study is implemented in association with the study "J-TAIL-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer, UMIN study…
- Trial name
- NCT04818983
- Where
- 95 sites in Japan
- Volunteers
- 470 people
- Sponsor
- Chugai Pharmaceutical
Non-Small Cell Lung Cancer
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
The purpose of study is to evaluate the safety, pharmacokinetics and anti-tumor effects of CKD-702 as a monotherapy and to determine the Recommended Phase 2 Dose(RP2D) in patients with advanced or metastatic non-small cell lung…
- Trial name
- CKD-702 (NCT04667975)
- Testing
- CKD-702
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Lung Cancer
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking.
- Trial name
- NCT05965557
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Metastatic Non-small Cell Lung Cancer
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC
AC0010 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR.
- Trial name
- NCT02330367
- Testing
- AC0010
- Where
- 17 sites in China
- Volunteers
- 368 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Melanoma, Thyroid Cancer
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors.
- Conditions
- Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT02012231
- Testing
- PLX8394
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fore Biotherapeutics
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
HER2-mutant Non-Small Cell Lung Cancer
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter, multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus combination therapy in patients with non-small cell lung…
- Trial name
- NCT01827267
- Testing
- neratinib, temsirolimus
- Where
- 21 sites in United States, France
- Volunteers
- 62 people
- Sponsor
- Puma Biotechnology, Inc.
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose…
- Trial name
- NCT05767892
- Testing
- YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
- Where
- 52 sites in China
- Volunteers
- 350 people
- Sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.